Product Images Doxazosin Mesylate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Doxazosin Mesylate NDC 43353-739 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 8 mg - 43353 646 60

Bottle Label 8 mg - 43353 646 60

This is a medication called Doxazosin Mesylate, which is available in a strength of 8mg and comes in a bottle of 90 tablets. The NOC number is 553084680.*

Bottle Label 2 mg - 43353 739 60

Bottle Label 2 mg - 43353 739 60

This is a medication package for Doxazosin Mesylate, containing 90 tablets of 2mg each. Doxazosin Mesylate is a medicine used to treat high blood pressure and urinary retention caused by enlarged prostate.*

Bottle Label 4 mg - 43353 740 60

Bottle Label 4 mg - 43353 740 60

This is a medication called Doxazosin Mesylate. It comes in the form of 90 tablets, and each tablet contains 4mg of the drug. No other information is available due to the presence of errors.*

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Image of the chemical structure of doxazosin mesylate. - doxazosin 1

Image of the chemical structure of doxazosin mesylate. - doxazosin  1

Table 3 SUMMARY OF EFFECTIVENESS DATA IN PLACEBO-CONTROLLED TRIALS - doxazosin 2

Table 3 SUMMARY OF EFFECTIVENESS DATA IN PLACEBO-CONTROLLED TRIALS - doxazosin  2

The text seems to be a table summarizing the effectiveness data in placebo-controlled trials evaluating the efficacy of doxazosin mesylate in treating BPH-related symptoms. The table includes information on symptom scores and maximum flow rates for each group and the number of patients in each study. The table shows that the participants who received doxazosin mesylate achieved better outcomes in terms of symptom relief and maximum flow rates compared to those who were given a placebo. There are also some notes at the bottom of the table explaining the changes observed and some additional details about the studies.*

Image of Figure 1-Study 1 - doxazosin 3

Image of Figure 1-Study 1 - doxazosin  3

The text describes a figure of a study with a graph showing the mean change in total symptom score from baseline over the duration of treatment in weeks. The x-axis shows the duration of treatment, and the y-axis represents the mean change score. No information is given about the symptoms or the study itself, other than it being referred to as "Study 1".*

Image of Figure 1-Study 1 - doxazosin 4

Image of Figure 1-Study 1 - doxazosin  4

This appears to be a chart or graph showing the Mean Increase in Maximum Urinary Flow Rate from baseline at different durations of treatment (in weeks) with a medication called Doxazosin. The measurements are in mL/sec and there seems to be a statistically significant increase compared to placebo (+ p <0.05). However, without additional context or visual inspection, it is difficult to provide further interpretation.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.